Status: Recruiting
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .
Participants needed: 8,000
Trial details
Phase: Phase 3Age: 20-45Biological sex: FemaleType: InterventionalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Jun 7, 2024Locations: 1
Eligibility criteria
Chinese women aged 20-45 who can provide legal identification and have a sexual... [+6]
Have been vaccinated with commercially available HPV vaccine in the past or plan... [+34]